This document discusses treatment of HER2 positive breast cancer. It describes HER2 as a tyrosine kinase receptor that is overexpressed in 15-30% of breast cancers and promotes cell proliferation. Testing methods like IHC and FISH are used to detect HER2 status. Targeted therapies have been developed that block HER2 signaling including Trastuzumab, Pertuzumab, Lapatinib, and T-DM1. Several neoadjuvant and adjuvant clinical trials are summarized that demonstrate improved outcomes when these anti-HER2 therapies are added to chemotherapy regimens for both early-stage and metastatic HER2 positive breast cancer.
What are the latest treatment advances for HER2-positive metastatic breast cancer? Eric Winer, MD, director of the Breast Cancer Program in the Susan F. Smith Center for Women's Cancers, discusses some of the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
What are the latest treatment advances for HER2-positive metastatic breast cancer? Eric Winer, MD, director of the Breast Cancer Program in the Susan F. Smith Center for Women's Cancers, discusses some of the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
Adjuvant Endocrine Therapy For Postmenopausal Breast CancerEmad Shash
Questions Covered in the presentation:
• Should patients receive an AI or Tamoxifen?
• Should patients receive monotherapy (AI or Tamoxifen alone) or sequential
therapy using both?
• 5 vs 10 years of therapy?
• If More than 5 years of endocrine therapy, which class to be used
Immunotherapy for Metastatic Triple Negative Breast Cancerbkling
Sylvia Adams, MD, medical oncologist, and associate professor at the NYU School of Medicine, discusses the latest research including the role of immunology in the treatment of triple negative metastatic breast cancer. This webinar was hosted on October 19, 2016.
Overview about evolution of the term Oligometastases,the paradigm and various states of oligometastases,treat options ,clinical trials and relevance in current clinical practice
Tried to summarise all landmark trials in carcinoma breast in radiation oncology,medical oncology as well in surgical oncology.
References taken from Devita Book,Breast Disease book from Springer,journals like NEJM,JAMA,LANCET,ANNL ONCOLOGY etc,internet,Perez book,Practical Clinical Oncology by Hanna etc textbooks.
Thanks.
How can immunotherapy be used to treat metastatic breast cancer? Ian Krop, MD, PhD, discusses the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 and hosted by the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
Adjuvant Endocrine Therapy For Postmenopausal Breast CancerEmad Shash
Questions Covered in the presentation:
• Should patients receive an AI or Tamoxifen?
• Should patients receive monotherapy (AI or Tamoxifen alone) or sequential
therapy using both?
• 5 vs 10 years of therapy?
• If More than 5 years of endocrine therapy, which class to be used
Immunotherapy for Metastatic Triple Negative Breast Cancerbkling
Sylvia Adams, MD, medical oncologist, and associate professor at the NYU School of Medicine, discusses the latest research including the role of immunology in the treatment of triple negative metastatic breast cancer. This webinar was hosted on October 19, 2016.
Overview about evolution of the term Oligometastases,the paradigm and various states of oligometastases,treat options ,clinical trials and relevance in current clinical practice
Tried to summarise all landmark trials in carcinoma breast in radiation oncology,medical oncology as well in surgical oncology.
References taken from Devita Book,Breast Disease book from Springer,journals like NEJM,JAMA,LANCET,ANNL ONCOLOGY etc,internet,Perez book,Practical Clinical Oncology by Hanna etc textbooks.
Thanks.
How can immunotherapy be used to treat metastatic breast cancer? Ian Krop, MD, PhD, discusses the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 and hosted by the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
Breast Cancer - Molecular Basis of HER2+ DiseaseFaryn
This presentation was part of a graduate level advanced molecular cell biology course. It reviews Breast Cancer epidemiology, signs 7 symptoms, diagnosis, genetic testing, hormonal testing and treatment options (briefly), then discusses the specifics of HER2+ cases at the cellular level. It shows how Herceptin and Tykerb work in the cell to block signal cascades, etc.
Learn about the latest research and treatment for ER+ breast cancer. Erica Mayer, MD, MPH, medical oncologist with the Susan F. Smith Center for Women's Cancers, discusses new clinical trials and treatment options for this subset of breast cancer patient.
This presentation was originally given on Oct. 17, 2015, at the Metastatic Breast Cancer Forum, hosted by the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, in Boston, Mass.
Learn more: http://www.susanfsmith.org
Learn about the latest treatment options for advanced triple-negative breast cancer. Nancy Lin, MD, a breast oncologist in the Susan F. Smith Center for Women's Cancers at Dana-Farber, discusses new research.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held at Dana-Farber Cancer Institute in Boston, Mass. on Oct. 17, 2015.
More information is available at http://www.susanfsmith.org.
Join Dr. Erica Mayer, medical oncologist at Dana-Farber/Brigham and Women's Cancer Center, to learn about exciting metastatic breast cancer developments from the past year. Dr. Mayer presents an overview on metastatic breast cancer and the subgroups, including Hormone Receptive, HER2+, and Triple Negative, and highlights recent advances for each of these subgroups. She also discusses the importance of clinical trials and what it means to participate in a clinical trial.
For more information on the Breast Cancer Treatment Center at Dana-Farber Cancer Institute, please visit:
http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Breast-Cancer-Treatment-Center.aspx
What's the latest in breast cancer treatment and research? Erica Mayer, MD, MPH, a medical oncologist in the Susan F. Smith Center for Women's Cancers, shares the latest breast cancer news.
This presentation was originally given on Oct. 16, 2015, at the annual Young Women with Breast Cancer Forum, hosted by the Program for Young Women with Breast Cancer in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, in Boston, Mass.
Learn more: http://www.susanfsmith.org
Radiotherapy and Cetuximab in head and neck cancer.pptxNamrata Das
Radiotherapy and Cetuximab in head and neck cancer
Bonner trial
RTOG 0522
TREMPLIN
RTOG 1016
De-Escalate trial
TROG
HN.6
PembroRAD
Nimotuzumab
Panitimumab
While the world was focused on covid 19, WHO has made and issued consolidated guidelines making changes in how to prevent, diagnose and treat tuberculosis.
Treatment Deintensification in HPV positive head and neck cancerDr Rushi Panchal
This ppt is providing detail of current status and future direction of treatment deintensification strategies of head and neck cancer in era of HPV positive sq cell carcinoma.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
1. Treatment of HER2 Positive
Breast Cancer
Dr. Manar Almusarhed
24 Mar 2016
Milton Keynes University Hospital
2. Human Epidermal growth factor Receptor 2
• One of the Tyrosine Kinase Receptors
(HER1,HER2,HER3,HER4)
• Function : Heterodimerization with
other family members such as HER1
and HER3 initiates a variety of signaling
pathways leading to Cell proliferation,
survival, differentiation, angiogenesis,
and invasion.
3. Overexpression
• HER2 is overexpressed in 15–30%of
invasive breast cancer.
• Associated with high-grade disease,
nodal metastases and tumour size.
• HER2 Overexpression occurs also in
other forms of cancers also such as
stomach, ovary, uterine serous
endometrial carcinoma, colon,
bladder, lung, uterine cervix, head and
neck, and esophagus.
4. Testing for HER2
• Immunohistochemistry IHC
• Fluorescence In Situ
Hybridization (FISH).
5. Targeting HER2
A. Trastuzumab: Blocks domain IV
HER2 (1998)
B. Pertuzumab: Blocks domain II
HER2 (2007)
C. Lapatinib : Blocks Intracellular ATP
pocket of HER1 & HER2 (2012)
D. Ado-Trastuzumab emsantine
(T-DM1) : monoclonal Ab –
Cytotoxic drug (2013)
7. Buzdar et al., 2005
• Forty-two patients with HER2-positive
disease randomly assigned to either
four cycles of paclitaxel followed by
four cycles of FEC or to the same
chemotherapy with simultaneous
weekly trastuzumab for 24 weeks
• Results: pCR rates were 26% and 66 %
for chemotherapy (n = 16) and
trastuzumab plus chemotherapy (n =
18), respectively (P = .02)
• Conclusion: Adding trastuzumab to
chemotherapy significantly increased
pCR.
8. NOAH trial : Phase III
• 235 patients with HER2-positive disease were
enroled, of whom 118 received
chemotherapy alone and 117 received
chemotherapy plus trastuzumab.
• Results: pCR rates were 43% and
22% for chemotherapy and Trustuzumanb
plus chemotherapy respectively.
• Conclusion: Adding trastuzumab to
chemotherapy significantly increased pCR.
11. UK EPHOS-B trial (2016)
• Multicentre, 2-part randomised trial in
patients with operable newly diagnosed
HER2+ primary BC
• EPHOS-B was designed to measure the effect
of 10–12 days' pre-operative anti-HER2
therapy on proliferation and apoptosis in
HER2+ BC patients
• Trial started with part1 then amended to part
2
• Conclusion : The early reduction or absence
of invasive disease in approximately quarter
of patients after only 11 days' preoperative
combination HER2 therapy identifies cancers
addicted to the HER2 pathway.
MDR: Minimal Residual Disease < 5mm
IQR: interquartile range
13. HERA trial
• Randomised three-arm
multicente comparison of 1 year
and 2 years of Trustuzumab Vs
no Trustuzumab in women who
have completed chemotherapy.
14. HERA trial
• Findings:
• Conclusion: Two years of adjuvant
Trastuzumab is not more effective
than is 1 year of treatment .
One year of treatment provides a
significant disease-free and overall
survival benefit compared with
observation.
Endpoint One year
Herceptin vs.
observation*
One year vs.
two years
Herceptin**
Disease-free
survival
•HR=0.76,
p<0.0001
•24% reduction
in the risk of
disease
recurrence
•HR=0.99,
p=0.86
•No difference
Overall survival •HR=0.76,
p=0.0005
•24% reduction
in the risk of
death
•HR=1.05,
p=0.63
•No difference
15. BCIRG 006 trial
• 3222 women with HER2-positive early-stage
breast cancer enroled in this trial.
16. BCIRG 006 trial
• Findings: The estimated disease-free
survival rates at 5 years were 75%
among patients receiving AC-T, 84%
among those receiving AC-T plus
trastuzumab, and 81% among those
receiving TCH.
17. BCIRG 006 trial
• Overall survival:
• Conclusion: Addition of 1 year
of adjuvant Trastuzumab
significantly improved disease-
free and overall survival among
women with HER2-positive
breast cancer.
18. NCCTG N9831 and NSABP B-31
• 4,046 patients with HER2-positive
operable breast cancer were enrolled
to receive doxorubicin and
cyclophosphamide followed by
paclitaxel with or without
Trastuzumab in both trials.
21. NCCTG N9831 and NSABP B-31
• Results: Median time on study was 8.4 years.
Adding trastuzumab to chemotherapy led to a
37% relative improvement in OS (hazard ratio
[HR], 0.63; 95% CI, 0.54 to 0.73; P < .001) and
an increase in 10-year OS rate from 75.2% to
84%. These results were accompanied by an
improvement in DFS of 40% (HR, 0.60; 95% CI,
0.53 to 0.68; P < .001) and increase in 10-year
DFS rate from 62.2% to 73.7.
• Conclusion: Addition of trastuzumab to
paclitaxel after doxorubicin and
cyclophosphamide in early-stage HER2-
positive breast cancer results in a substantial
and durable improvement in survival as a
result of a sustained marked reduction in
cancer recurrence.
22. Metastatic disease trials
• Salmon et al (2001)
• Marty et al (2005)
• CONCLUSIONS:Trastuzumab increases
the clinical benefit of first-line
chemotherapy in metastatic breast
cancer that overexpresses HER2.
23. CLEOPATRA trial
• randomized, double-blind,
placebo-controlled, phase III
trial
• 808 Patients were enrolled in
this trials
24. CLEOPATRA trial
• Conclusion: significant
improvement in overall survival
with pertuzumab, trastuzumab,
and docetaxel in patients with
HER2-positive metastatic breast
cancer, compared with placebo,
trastuzumab, and docetaxel
25. EMILIA trial
• multi-center, international
randomized study of T-DM1 vs.
capecitabine and lapatinib, for
trastuzumab refractory HER2+
metastatic breast cancer.
27. EMILIA trial
• Conclusion: T-DM1 significantly
prolonged progression-free and
overall survival with less toxicity
than Lapatinib plus Capecitabine
in patients with HER2-positive
advanced breast cancer
previously treated with
Trastuzumab and a Taxane